Data spans various cardiometabolic conditions, including type 2 diabetes (T2D), obesity, peripheral arterial disease, and chronic kidney disease SOUL, a phase 3 trial, explored reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and atherosclerotic cardiovascular and/or chronic kidney disease 1 SCORE study evaluated use of semaglutide 2.4 mg and MACE risk reduction in real-world settings 2 STRIDE phase 3 data offers new insights on functional capacity with the use of injectable semaglutide 1 mg for people with type 2 diabetes and peripheral artery disease 3 PLAINSBORO, N.J.
, March 17, 2025 /PRNewswire/ -- Novo Nordisk today announced new data for semaglutide medicines to be presented at the American College of Cardiology 74th Annual Scientific Session and Expo (ACC.25). These new cardiometabolic data, spanning multiple, inter-related chronic diseases, will provide new information about semaglutide medicines to reduce cardiovascular (CV) risk and improve functional capacity in treating certain patient populations.
"Cardiovascular disease is the leading cause of death globally, disproportionately affecting people living with diabetes and obesity. It remains one of the most pressing diseases of our time and it carries a high clinical burden," said Anna Windle , PhD, Senior Vice President, NAO Clinical Development, Medical and Regulatory Affairs at Novo Nordisk Inc. "We continue to build on our over 100-year legacy of cutting-edge science and.